How Do Skyrizi and Humira Work?
Skyrizi (risankizumab) targets interleukin-23 (IL-23), a specific cytokine driving inflammation in autoimmune diseases like psoriasis and Crohn's. Humira (adalimumab) is a broader TNF-alpha inhibitor that blocks tumor necrosis factor, a key inflammatory protein involved in multiple conditions.[1]
What Conditions Do They Treat?
Both treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Humira has a wider FDA-approved list, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, hidradenitis suppurativa, and uveitis. Skyrizi focuses on IL-23-driven diseases, with approvals mainly for psoriasis, psoriatic arthritis, and Crohn's.[1][2]
How Are They Administered and Dosed?
Skyrizi starts with two 150 mg subcutaneous injections at week 0, then 150 mg every 12 weeks. Humira uses 40-80 mg injections every 1-2 weeks, depending on the condition. Skyrizi's less frequent dosing improves convenience for long-term use.[1][2]
How Effective Are They Head-to-Head?
Skyrizi often shows higher skin clearance rates in psoriasis trials (e.g., 75-90% achieving PASI 90 at one year) compared to Humira's 60-70%. In Crohn's, Skyrizi achieves endoscopic response in about 40% of patients versus Humira's 25-30%. Direct comparisons are limited, but Skyrizi edges out in IL-23-specific efficacy.[3]
What About Side Effects and Safety?
Both carry black-box warnings for infections and malignancy risks. Humira, as a TNF inhibitor, has higher tuberculosis reactivation rates. Skyrizi reports fewer serious infections due to its targeted mechanism. Common issues for both include injection-site reactions and upper respiratory infections; Humira adds more headache and rash reports.[1][2]
Who's Behind Them and What's the Cost Difference?
AbbVie makes both—Skyrizi is newer (approved 2019), Humira older (2002). Skyrizi costs $6,000-$7,000 per dose (less frequent), totaling ~$20,000-$25,000 yearly. Humira runs $6,000-$7,000 monthly, or $70,000+ annually without discounts. Biosimilars have slashed Humira prices since 2023; Skyrizi lacks them yet.[4]
When Do Patents Expire?
Humira's key patents expired in 2023, enabling biosimilars. Skyrizi's main composition patent runs to 2032-2033, with others into 2037; challenges are ongoing.[5]
[1]: FDA Labels - Skyrizi (https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/761061s015lbl.pdf), Humira (https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125057s412lbl.pdf)
[2]: Drugs.com - Skyrizi vs Humira (https://www.drugs.com/compare/skyrizi-vs-humira)
[3]: NEJM - Head-to-Head Psoriasis Trials (https://www.nejm.org/doi/full/10.1056/NEJMoa1903663)
[4]: GoodRx Pricing Data (https://www.goodrx.com/compare/skyrizi-vs-humira)
[5]: DrugPatentWatch.com - Skyrizi Patents (https://www.drugpatentwatch.com/p/tradename/SKYRZI), Humira Patents (https://www.drugpatentwatch.com/p/tradename/HUMIRA)